PMID- 38214357
OWN - NLM
STAT- MEDLINE
DCOM- 20240206
LR  - 20240206
IS  - 2212-3970 (Electronic)
IS  - 1574-8928 (Linking)
VI  - 19
IP  - 2
DP  - 2024
TI  - YBX1, Targeted By Microrna-382-5p, Promotes Laryngeal Squamous Cell Carcinoma 
      Progression via Modulating RAS/MAPK Signaling.
PG  - 176-187
LID - 10.2174/1574892818666230207091720 [doi]
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is the most common cancer of 
      head and neck cancer. Y-box binding protein-1 (YBX1) has tumor-promoting effects 
      in some types of cancers. However, its role in LSCC remains unknown. This study 
      set out to identify the role of YBX1 in LSCC. METHODS: Bioinformatics analysis of 
      the Gene Expression Omnibus (GEO) database and our cohort data were used to 
      explore the association of YBX1 expression with clinicopathological factors in 
      LSCC. Then, cells with stably or transiently transfected with plasmid or siRNA 
      were constructed to assess the effect of loss and gain of YBX1 on the biological 
      phenotypes of LSCC cells in vitro. In addition, subcutaneous xenograft and 
      orthotopic liver tumor mouse models were constructed for validation. The 
      interrogated miRNA databases and subsequent luciferase reporter assays were used 
      to confirm the miR-382-5p target of YBX1. At last, KEGG enrichment annotation 
      from TGCA data was used for downstream analyses of miR-382-5p/YBX1 and verified 
      by PCR and Western immunoblotting. RESULTS: The results showed that significant 
      upregulation of YBX1 in LSCC tumors was correlated with advanced TNM stage and 
      poor prognosis. Knockdown of YBX1 markedly impaired the proliferative, invasive, 
      and migratory activity of Tu212 cells. We confirmed that miR-382-5p targets YBX1 
      to mediate LSCC progression both in vitro and in vivo. We further confirmed that 
      miR-382-5p/YBX1 modulated the Ras/MAPK signaling axis to regulate the progression 
      of LSCC. CONCLUSION: Together, our results indicated that YBX1 is an important 
      promoter of LSCC progression. And miR-382-5p/YBX1/RAS/MAPK signaling pathway can 
      be perceived as a promising target in the treatment of LSCC.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Zeng, Wen
AU  - Zeng W
AD  - Department of Head and Neck Surgery, Ganzhou Cancer Hospital, Jiangxi Province, 
      People's Republic of China.
FAU - Pan, Yiyun
AU  - Pan Y
AD  - Department of Oncology, Ganzhou Cancer Hospital, Jiangxi Province, People's 
      Republic of China.
FAU - Chen, Hailong
AU  - Chen H
AD  - Department of Oncology, Ganzhou Cancer Hospital, Jiangxi Province, People's 
      Republic of China.
FAU - Lei, Xianhua
AU  - Lei X
AD  - Department of Pathology, Ganzhou Cancer Hospital, Jiangxi Province, People's 
      Republic of China.
FAU - Zhang, Xiangmin
AU  - Zhang X
AD  - Department of Head and Neck Surgery, Ganzhou Cancer Hospital, Jiangxi Province, 
      People's Republic of China.
AD  - Department of Otolaryngology, Longgang E.N.T hospital & Shenzhen Key Laboratory 
      of E.N.T, Institute of E.N.T Shenzhen, Guangdong Province, People's Republic of 
      China.
LA  - eng
GR  - 20181BAB205037/Natural Science Foundation of Jiangxi Province/
GR  - GZ2018ZSF363/Ganzhou Cancer Hospital Department Guidance Plan Project/
PT  - Journal Article
PL  - United Arab Emirates
TA  - Recent Pat Anticancer Drug Discov
JT  - Recent patents on anti-cancer drug discovery
JID - 101266081
RN  - 0 (MicroRNAs)
RN  - 0 (MIRN382 microRNA, human)
RN  - 0 (Y-Box-Binding Protein 1)
RN  - 0 (YBX1 protein, human)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mice
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - *Laryngeal Neoplasms/genetics/metabolism/pathology
MH  - *MicroRNAs/genetics/metabolism
MH  - *Squamous Cell Carcinoma of Head and Neck/genetics/metabolism/pathology
MH  - *Y-Box-Binding Protein 1/genetics/metabolism
OTO - NOTNLM
OT  - Laryngeal cancer
OT  - Ras signaling
OT  - Y-box binding protein-1
OT  - microRNA
OT  - mitogenactivated protein kinase.
OT  - squamous cell carcinoma
EDAT- 2024/01/12 12:42
MHDA- 2024/01/15 12:42
CRDT- 2024/01/12 07:55
PHST- 2022/10/16 00:00 [received]
PHST- 2022/11/22 00:00 [revised]
PHST- 2022/11/25 00:00 [accepted]
PHST- 2024/01/15 12:42 [medline]
PHST- 2024/01/12 12:42 [pubmed]
PHST- 2024/01/12 07:55 [entrez]
AID - PRA-EPUB-129329 [pii]
AID - 10.2174/1574892818666230207091720 [doi]
PST - ppublish
SO  - Recent Pat Anticancer Drug Discov. 2024;19(2):176-187. doi: 
      10.2174/1574892818666230207091720.